Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure.

about

Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure.

Item

http://www.wikidata.org/entity/Q49232014

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Predicting the visual acuity f ...... ng for macular microstructure.

@en

Predicting the visual acuity f ...... ng for macular microstructure.

@nl

type

Item

label

Predicting the visual acuity f ...... ng for macular microstructure.

@en

Predicting the visual acuity f ...... ng for macular microstructure.

@nl

prefLabel

Predicting the visual acuity f ...... ng for macular microstructure.

@en

Predicting the visual acuity f ...... ng for macular microstructure.

@nl

P1476

Predicting the visual acuity f ...... ng for macular microstructure.

@en

P2093

Haiyang Liu

http://www.w3.org/2001/XMLSchema#string

Jie Shen

http://www.w3.org/2001/XMLSchema#string

Suyan Li

http://www.w3.org/2001/XMLSchema#string

Zhengpei Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study

Grid laser treatment in macular branch retinal vein occlusion.

Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion.

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion.

Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results.

Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

P304

890-896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2017.5437

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29399095

http://www.w3.org/2001/XMLSchema#string

P921

microstructure

P932

5772794

http://www.w3.org/2001/XMLSchema#string